Siemens AG plans to list its healthcare imaging and diagnostics business, Siemens Healthineers, on the Frankfurt Stock Exchange during the first half of 2018, Europe’s largest industrial manufacturing company said on 29 November.
AstraZeneca Plc has entered into a partnership with the Chinese-government backed Future Industry Investment Fund (FIIF) to create a stand-alone, joint venture company called Dizal Pharmaceutical that will develop and commercialise new medicines in China.
Avelumab, a checkpoint antibody that is the mainstay of Merck KGaA’s immuno-oncology portfolio, has failed to show superior overall survival in patients with metastatic gastric cancer compared with chemotherapy. The data is from a Phase 3 trial called Javelin Gastric 300.
Scientists at the University of Tampere in Finland and the Karolinska Institutet in Sweden have tested a vaccine targeting a pathogenic strain of an enterovirus in mice and found that it protected against Type 1 diabetes. The findings were reported in the 20 November 2017 edition of Diabetologia.
An immuno-oncology combination that had initially produced an objective response in a Phase 1/2 trial of patients with head and neck cancer, failed to show benefit in an extended patient population, Innate Pharma SA announced on 22 November.
A new small molecule drug intended to treat cystic fibrosis patients with the F508del gene mutation has been well tolerated in patients in a Phase 2 study, paving the way for its use as part of a triple therapy, Galapagos NV announced on 19 November.
Roche has reported positive Phase 3 results for two different antibody therapeutics putting it in a leadership position for treating both non-small cell lung cancer and haemophilia A. The cancer trial was significant because it showed the benefits of using a checkpoint inhibitor as part of a triple therapy.
What will it take to build an integrated capital market in Europe? This question engaged executives at a BioEurope conference in Berlin on 6 to 8 November. The answer was both short and sweet, and long and complex.
Ablynx NV, the Belgian antibody specialist, has released financial results for the first nine months of 2017 which show an operating loss due to significant outlays for research and development, but a strong cash balance. This was later augmented by a successful IPO on US Nasdaq.
Crispr Therapeutics AG and its joint venture with Bayer AG called Casebia Therapeutics LLP have signed an exclusive collaboration agreement with CureVac AG to develop therapeutics that exploit both the new gene editing and messenger RNA (mRNA) technologies.